Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Esophageal and Esophagogastric Junction Cancers, Version 1.2015 JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Ajani, J. A., D'Amico, T. A., Almhanna, K., Bentrem, D. J., Besh, S., Chao, J., Das, P., Denlinger, C., Fanta, P., Fuchs, C. S., Gerdes, H., Glasgow, R. E., Hayman, J. A., Hochwald, S., Hofstetter, W. L., Ilson, D. H., Jaroszewski, D., Jasperson, K., Keswani, R. N., Kleinberg, L. R., Korn, W. M., Leong, S., Lockhart, A. C., Mulcahy, M. F., Orringer, M. B., Posey, J. A., Poultsides, G. A., Sasson, A. R., Scott, W. J., Strong, V. E., Varghese, T. K., Washington, M. K., Willett, C. G., Wright, C. D., Zelman, D., McMillian, N., Sundar, H. 2015; 13 (2): 194-227

Abstract

Esophageal cancer is the sixth most common cause of cancer deaths worldwide. Adenocarcinoma is more common in North America and Western European countries, originating mostly in the lower third of the esophagus, which often involves the esophagogastric junction (EGJ). Recent randomized trials have shown that the addition of preoperative chemoradiation or perioperative chemotherapy to surgery significantly improves survival in patients with resectable cancer. Targeted therapies with trastuzumab and ramucirumab have produced encouraging results in the treatment of advanced or metastatic EGJ adenocarcinomas. Multidisciplinary team management is essential for patients with esophageal and EGJ cancers. This portion of the NCCN Guidelines for Esophageal and EGJ Cancers discusses management of locally advanced adenocarcinoma of the esophagus and EGJ.

View details for Web of Science ID 000349834400011

View details for PubMedID 25691612